A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa

NCT06201858 · tracked via the Priya Life Science USA tracker

Sponsor

Power Life Sciences Inc

Phase

Observational

Started

2025-01

Last updated

2024-02-12

Condition(s) studied

Hidradenitis Suppurativa

Study summary

This study aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in hidradenitis suppurativa clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors.

Ultimately, this trial endeavors to deepen our understanding of the factors impacting hidradenitis suppurativa clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Aged ≥ 18 years old * Diagnosis of hidradenitis suppurativa * Able to comprehend the investigational nature of the protocol and provide informed consent Exclusion Criteria: * Female patients who are currently pregnant or nursing * Inability to perform regular electronic reporting * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Primary outcome measure(s)

Number of hidradenitis suppurativa patients who decide to enroll in a clinical research — 3 months
Rate of hidradenitis suppurativa patients who remain in clinical trial to trial completion — 12 months

Trial sites (1)

Facility	City	Region	Status
Power Life Sciences	San Francisco	California

More Power Life Sciences Inc. trials in the USA

Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research Starting soon

Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients Starting soon

Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study Starting soon

Delving Into Participation Trends in Renal Cell Carcinoma Studies Starting soon

Examining Engagement Trends Among Participants in Peripheral Neuropathy Clinical Research Starting soon

Other trials for the same condition

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy Active, not recruiting

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) Active, not recruiting

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) Active, not recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06201858 on ClinicalTrials.gov ↗ ← All trials in the USA